Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvation Bio Inc. Class A Common Stock (NY:NUVB)

4.730 -0.290 (-5.78%)
Official Closing Price Updated: 4:10 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nuvation Bio Inc. Class A Common Stock

< Previous 1 2 3 4 5 Next >
Nuvation Bio (NUVB) Q3 2025 Earnings Transcript
Nuvation Bio (NUVB) Q3 2025 Earnings Transcript 
Via The Motley Fool
Topics Earnings
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Earnings Scheduled For November 3, 2025
 
Via Benzinga
Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock
Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock 
Via The Motley Fool
Topics Regulatory Compliance
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio
Via Business Wire
4 Analysts Assess Nuvation Bio: What You Need To Know
 
Via Benzinga
Analyst Expectations For Nuvation Bio's Future
 
Via Benzinga
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
From Nuvation Bio
Via Business Wire
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025
From Nuvation Bio
Via Business Wire
Why Nuvation Bio Stock Is Skyrocketing Today
The bulls are lining up on Wall Street for this up-and-coming biotech stock. 
Via The Motley Fool
Earnings Scheduled For August 7, 2025
 
Via Benzinga
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
From Nuvation Bio
Via Business Wire
Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
From Nuvation Bio
Via Business Wire
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
From Nuvation Bio
Via Business Wire
Guidewire Software, Samsara, Zumiez And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Top 2 Health Care Stocks That May Plunge This Month
 
Via Benzinga
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio
Via Business Wire
NUVB Sales Jump 1,043% on Drug Launch
Via The Motley Fool
Topics Intellectual Property
Nuvation Bio Inc (NYSE:NUVB) Reports Mixed Q2 2025 Results with Strong Revenue Beat but Cautious Market Reaction
Nuvation Bio (NUVB) reported Q2 2025 results with a massive revenue beat ($4.83M vs. $364K est.) driven by IBTROZI launch, but EPS met expectations (-$0.17). Cash at $607.7M, pipeline progressing. 
Via Chartmill
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
From Nuvation Bio
Via Business Wire
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
From Nuvation Bio
Via Business Wire
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
From Nuvation Bio
Via Business Wire
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers
From Nuvation Bio
Via Business Wire
Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval
FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing high response rates. 
Via Benzinga
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
From Nuvation Bio
Via Business Wire
Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.